$IFRX

Dividend Declaration

iFOREX Financial Trading Holdings (LSE:IFRX) said shareholders approved at its 18 June 2026 AGM a final dividend of $0.055 per ordinary share for the year ended 31 Dec 2025. Ex-dividend date is 25 June 2026, record date 26 June 2026, and payment date 24 July 2026.

Original reporting
Published Jun 18, 2026, 4:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 5:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dividend Declaration — source image
Decision brief

The 30-second read

$IFRXBullishLow
01

Why it matters

The AGM approval confirms a final dividend payout schedule for FY ended 31 Dec 2025, which can influence short-term trading around the ex-dividend date but does not indicate changes to operating outlook.

02

Market read

A confirmed dividend timetable (ex-date, record date, pay date) provides a near-term, mechanical trading reference point for dividend capture and income-focused positioning.

03

What to watch

Traders may focus more on upcoming earnings or regulatory developments than on a routine final dividend timetable.

Relevance 4/10Novelty 3/10Timing: Ahead of the 25 June 2026 ex-dividend date; pay date 24 July 2026.

Background

The company (iFOREX) is an LSE-listed fintech broker that operates a proprietary online/mobile CFD trading platform.

Company-level read

Ticker impact

$IFRXBullishMedium confidence
Context

iFOREX shareholders approved a final dividend of USD 0.055 per ordinary share, with ex-dividend 25 June 2026 and pay date 24 July 2026.

Expected impact

Modest, short-lived impact around the 25 June 2026 ex-dividend date; otherwise limited fundamental repricing.

Evidence & confidence

The article discloses the declared final dividend amount and the full dividend timetable, but provides no earnings, guidance, or balance-sheet change.

Market effects

Limited read-across for the CFD/brokerage fintech sector; this is a company-specific payout decision.

Minor for UK-listed fintechs; primarily affects LSE dividend-focused flows.

Low; dividend is denominated in USD but tied to a single issuer’s shareholder base.

Counterpoint

Dividend size may be too small to matter for valuation; any price move may be mechanical around ex-date rather than signaling improved fundamentals.

Key entities

  • iFOREX Financial Trading Holdings Ltd.

    LSE-listed fintech broker; declared final dividend USD 0.055 per ordinary share for FY2025.

  • Annual General Meeting (AGM)

    Shareholders approved the final dividend at the AGM held on the article’s publication date.

Related articles

$IFRXMedAI 8/10

InflaRx plans two phase 2 AAV trials starting in 2027

InflaRx (IFRX) plans two Phase 2 trials for izicopan in ANCA-associated vasculitis, starting in 2027. The trials will involve 35 patients per arm and focus on renal involvement and glucocorticoid replacement. The company has €153.3M in cash, expected to fund operations through 2029. Izicopan has shown no safety concerns in 197 human subjects. Additional trials in IgA nephropathy and a Phase 3 trial in China are also planned.

$IFRXMedAI 8/10

An experimental drug reduced kidney injury in two animal models

InflaRx N.V. (IFRX) presented pre-clinical data showing its drug izicopan reduced kidney injury in two animal models. The study demonstrated izicopan's potential for treating complement-driven kidney diseases, with significant improvements in renal function markers and histopathological scores. The company plans to develop izicopan for ANCA-associated vasculitis and additional renal indications.

$IFRXMedAI 8/10

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

InflaRx N.V. (IFRX) will present pre-clinical data on its drug izicopan at Kidney Week 2026. Izicopan, an oral C5a receptor antagonist, showed promising results in kidney disease models and other inflammatory conditions. The company plans to develop izicopan for ANCA-associated vasculitis and renal diseases, highlighting its potential as a best-in-class treatment.

$IFRXMed

InflaRx N.V. (IFRX): Financial results for Q2 2026

InflaRx N.V. (IFRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones • Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned • Initiated feasibility ass

$ABBVMed

AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals

AbbVie has agreed to pay up to $757m for rights to two migraine drugs from Brise Pharmaceuticals. Brise will handle discovery, while AbbVie manages development and commercialization. The deal includes milestone payments and potential royalties. Brise's CEO called it a validation of their research platform. The migraine market was valued at $17.2bn in 2023, with unmet treatment needs.